An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
Public ClinicalTrials.gov record NCT04980495. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis
Study identification
- NCT ID
- NCT04980495
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- argenx
- Industry
- Enrollment
- 69 participants
Conditions and interventions
Interventions
- Efgartigimod IV Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2021
- Primary completion
- Aug 23, 2023
- Completion
- Oct 5, 2025
- Last update posted
- May 26, 2026
2021 – 2025
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site 10 - US0010007 | Carlsbad | California | 92011 | — |
| Investigator Site 7 - US0010001 | Orange | California | 92868 | — |
| Investigator Site 9 - 0010006 | Boca Raton | Florida | 33487 | — |
| Investigator Site 15 - US0010014 | Coral Springs | Florida | 33067 | — |
| Investigator Site 16 - US0010009 | Augusta | Georgia | 30910 | — |
| Investigator Site 8 - US0010003 | Chicago | Illinois | 60611 | — |
| Investigator Site 6 - US0010008 | Meadows | Illinois | 60008 | — |
| Investigator Site 12 - US0010004 | Kansas City | Kansas | 66160 | — |
| Investigator Site 13 - US0010013 | Portland | Oregon | 97239 | — |
| Investigator Site 17 - US0010012 | Philadelphia | Pennsylvania | 19104 | — |
| Investigator Site 11 - US0010011 | Austin | Texas | 78756 | — |
| Investigator Site 14 - US0010010 | Richmond | Virginia | 23219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04980495, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 26, 2026 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04980495 live on ClinicalTrials.gov.